Thomas Decker Selected Research

Immunotoxins (Immunotoxin)

5/2012	The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
4/2004	Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
2/2002	Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Decker Research Topics

Disease

36	Neoplasms (Cancer) 01/2022 - 02/2002
32	Breast Neoplasms (Breast Cancer) 02/2022 - 02/2005
21	Infections 10/2021 - 12/2002
17	Colorectal Neoplasms (Colorectal Cancer) 07/2022 - 03/2011
13	Inflammation (Inflammations) 10/2021 - 05/2004
10	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2022 - 02/2002
6	Disease Progression 01/2022 - 09/2007
6	Colitis 11/2015 - 11/2012
6	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2015 - 07/2003
4	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 05/2012
3	Bites and Stings (Sting) 01/2020 - 08/2014
3	Lymphoma (Lymphomas) 01/2018 - 07/2003
3	Sepsis (Septicemia) 12/2016 - 03/2003
3	Necrosis 08/2009 - 02/2008
3	Genetic Translocation (Chromosomal Translocation) 10/2006 - 07/2003
2	Microsatellite Instability 07/2022 - 01/2020
2	Renal Cell Carcinoma (Grawitz Tumor) 12/2021 - 01/2020
2	Neoplasm Metastasis (Metastasis) 12/2021 - 01/2021
2	Noninfiltrating Intraductal Carcinoma (DCIS) 06/2018 - 01/2018
2	Carcinoma (Carcinomatosis) 06/2018 - 12/2003
2	Carcinogenesis 01/2016 - 12/2011
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/2012 - 09/2006
2	Hairy Cell Leukemia 05/2012 - 02/2002
2	Listeriosis (Listeria Infection) 01/2012 - 12/2002
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2006 - 07/2003
2	Septic Shock (Toxic Shock Syndrome) 12/2003 - 05/2003
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022

Drug/Important Bio-Agent (IBA)

14	Bevacizumab (Avastin)FDA Link 01/2022 - 09/2014
11	Hormones (Hormone)IBA 01/2022 - 11/2012
10	Cetuximab (Erbitux)FDA Link 01/2022 - 03/2011
10	Interferon Type IIBA 01/2021 - 05/2003
9	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 03/2011
8	InterferonsIBA 10/2021 - 04/2008
7	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 12/2011
7	Everolimus FDA Link 04/2020 - 09/2007
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2011
6	ErbB Receptors (EGF Receptor)IBA 11/2021 - 12/2011
5	Leucovorin (Folinic Acid)FDA Link 01/2022 - 12/2011
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 03/2013
5	Proteins (Proteins, Gene)FDA Link 12/2016 - 12/2004
5	sodium sulfate (sodium bisulfate)FDA LinkGeneric 07/2015 - 11/2012
5	Dextrans (Dextran)FDA Link 07/2015 - 11/2012
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 03/2011
4	Phosphotransferases (Kinase)IBA 01/2021 - 11/2002
3	Fulvestrant (Faslodex)FDA Link 01/2022 - 01/2018
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 10/2006
3	Serine (L-Serine)FDA Link 10/2021 - 12/2003
3	STAT1 Transcription FactorIBA 10/2021 - 12/2011
3	CytokinesIBA 10/2021 - 01/2013
3	CyclinsIBA 01/2021 - 10/2006
3	Pharmaceutical PreparationsIBA 01/2021 - 03/2010
3	exemestane (Aromasin)FDA Link 04/2020 - 01/2019
3	Capecitabine (Xeloda)FDA Link 04/2020 - 03/2011
3	Phenobarbital (Luminal)FDA Link 04/2020 - 09/2016
3	TOR Serine-Threonine KinasesIBA 02/2019 - 10/2005
3	Biological ProductsIBA 06/2018 - 12/2004
3	AntibodiesIBA 01/2018 - 05/2012
3	16S Ribosomal RNAIBA 01/2015 - 11/2012
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013 - 05/2003
3	Immunotoxins (Immunotoxin)IBA 05/2012 - 02/2002
3	Cyclin D1IBA 02/2006 - 07/2003
2	NucleotidesIBA 07/2022 - 01/2020
2	human ERBB2 proteinIBA 02/2022 - 10/2015
2	LigandsIBA 01/2022 - 12/2020
2	Angiogenesis InhibitorsIBA 12/2021 - 11/2015
2	Sunitinib (Sutent)FDA Link 12/2021 - 01/2020
2	pazopanib FDA Link 12/2021 - 01/2020
2	Formaldehyde (Formol)FDA Link 12/2021 - 03/2013
2	Vinorelbine (Navelbine)FDA LinkGeneric 11/2021 - 08/2019
2	Alanine (L-Alanine)FDA Link 10/2021 - 01/2020
2	Aromatase InhibitorsIBA 01/2021 - 01/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 07/2017
2	Messenger RNA (mRNA)IBA 12/2020 - 04/2020
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 02/2014
2	ChromatinIBA 01/2018 - 08/2008
2	IronIBA 12/2016 - 06/2015
2	TYK2 Kinase (Tyrosine Kinase 2)IBA 11/2015 - 01/2009
2	LipopolysaccharidesIBA 10/2014 - 05/2003
2	FlagellinIBA 05/2014 - 11/2012
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 02/2014 - 04/2008
2	Cadherins (E-Cadherin)IBA 07/2013 - 12/2011
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 09/2012 - 04/2008
2	Interleukin-2 (IL2)IBA 11/2010 - 02/2008
2	Proteasome Endopeptidase Complex (Proteasome)IBA 02/2006 - 07/2003
2	Sirolimus (Rapamycin)FDA Link 10/2005 - 01/2003
2	OligodeoxyribonucleotidesIBA 12/2003 - 02/2002
1	idelalisibIBA 06/2022
1	obinutuzumabIBA 06/2022
1	tirabrutinibIBA 06/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2022
1	venetoclaxIBA 01/2022
1	ribociclibIBA 01/2022

Therapy/Procedure

27	Therapeutics 01/2022 - 01/2003
8	Drug Therapy (Chemotherapy) 01/2022 - 09/2014
3	Combination Drug Therapy (Combination Chemotherapy) 01/2022 - 01/2019
2	Operative Surgical Procedures 01/2019 - 02/2005
2	Transplantation 01/2018 - 12/2011
2	Adjuvant Chemotherapy 01/2017 - 10/2015
2	Neoadjuvant Therapy 12/2016 - 05/2010
1	Immunotherapy 01/2022